Posted by 
Introduction
Dementia, a progressive neurological disorder, is one of the UK’s most pressing healthcare challenges. The recent report entitled Are UK health systems dementia ready? by Future Health, sponsored by Lilly, highlights a frightening future for dementia in the UK; unless the rising tide of dementia cases and the substantial gap in diagnoses are addressed. Projections show that the number of dementia cases could rise to 1.5 million by 2040, and with a significant proportion (565,000 is the estimate) remaining undiagnosed, there is a critical need for systemic changes in how dementia is diagnosed and managed.
The Current Landscape
As of now, approximately 850,000 people in the UK live with dementia, but around 315,000 of these cases remain undiagnosed. This lack of diagnosis prevents many from accessing necessary care and support, including the potential benefits from new treatments. The disparity in diagnosis rates across different regions and countries within the UK underscores a fragmented approach to tackling this issue.
Regional Disparities in Diagnosis
The report uncovers significant variations in dementia diagnosis rates across the UK:
- England: Diagnosis rates are improving but still fall short of the two-thirds target, standing at 64.6%.
- Wales: The rate is 53.9%, a slight improvement from 2018 but not meeting the 3% annual improvement target set by the Dementia Action Plan.
- Northern Ireland and Scotland: These regions face challenges in accurately assessing diagnosis rates. Northern Ireland’s rate is estimated at 62%, while Scotland’s estimates range widely from 30-65%.
Within these countries, there are also stark variations among NHS Integrated Care Boards (ICBs):
- England: Only 36% of ICBs meet the two-thirds diagnosis target. Some of the lowest rates are in Herefordshire (53.7%), Somerset (55.3%), and Dorset (56.5%).
- Wales: Cardiff and Vale University Health Board boasts the highest diagnosis rate at 65.3%, compared to Powys Teaching Board’s 44.3%.
Projected Trajectories and Potential Outcomes
The report models three scenarios for dementia diagnosis rates by 2040:
- Status Quo: If diagnosis rates remain the same, over 565,000 people could be living with undiagnosed dementia, nearly a quarter of a million more than today.
- Improvement to Two-Thirds Target: Meeting the two-thirds target across all UK nations would still result in a significant increase in undiagnosed cases, up to 490,000.
- Optimistic Scenario: Increasing diagnosis rates to 80% across all regions could reduce undiagnosed cases to around 300,000, which is still a substantial number but represents an improvement.
Implications of Undiagnosed Dementia
Undiagnosed dementia means that individuals cannot access the necessary medical and support services, leading to a poorer quality of life and higher burdens on caregivers. Early diagnosis is crucial for managing symptoms, planning for future care needs, and accessing emerging treatments that could slow disease progression.
Recommendations and Calls to Action
The report strongly recommends several actions to address the diagnosis gap:
- System Readiness Plans: Each UK nation should publish a plan by the end of the year, preparing healthcare systems for new dementia treatments.
- Increased Investment: There should be a significant increase in funding for diagnostic capabilities and post-diagnostic support.
- Ambitious Diagnosis Targets: New, more ambitious targets should be set, supported by financial incentives to encourage achievement.
- Policy Updates: National strategies need revision and active implementation. For example, Scotland has recently published a new dementia strategy, while strategies in England, Wales, and Northern Ireland are outdated or expired.
Expert Opinions
Richard Sloggett, Programme Director at the Future Health Research Centre and report author, emphasizes the need for urgent investment and new targets. He highlights that “business as usual” will not meet the needs of the rising number of dementia patients. Laura Steele, President and General Manager of Lilly UK, points out the stark variation in diagnosis rates and the necessity for improved diagnostic capabilities to ensure equitable care access.
Dementia, The Poor Relation
Dementia is the poor relation of the major human disease family. In the UK, there is a significant difference in the amount of funding allocated to dementia research compared to, for example, cancer research.
As of recent figures, the UK government invests around £85 million annually in dementia research. This figure reflects approximately 0.25% of the annual cost of dementia to society, which stands at £26 billion (NIHR) (Alzheimer’s Research UK). The government has committed to doubling this funding to £160 million per year by 2024/25 as part of the Dame Barbara Windsor Dementia Mission (Dementia Statistics Hub) (Questions and Statements).
In contrast, cancer research receives substantially more funding. The government invested £269 million in cancer research in 2015/16, which is about 1.6% of cancer’s annual cost to the UK, estimated at £16.4 billion(Alzheimer’s Research UK).
This disparity highlights the need for increased investment in dementia research to better address the growing challenges posed by this condition as the population ages. For more detailed information on these figures and the government’s plans, you can refer to sources like Alzheimer’s Research UK and the Dementia Statistics Hub (NIHR) (Alzheimer’s Research UK).
Conclusion
The Future Health report paints a concerning picture of the UK’s preparedness for the growing dementia crisis. With projections showing a steep increase in dementia cases and significant numbers remaining undiagnosed, there is an urgent need for systemic reforms. Enhancing diagnostic capabilities, updating national strategies, and setting ambitious targets are essential steps toward ensuring that those affected by dementia receive timely and appropriate care. Policymakers, healthcare providers, and stakeholders must collaborate to build a healthcare system that is truly “dementia ready.”